These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 9674850)
1. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850 [TBL] [Abstract][Full Text] [Related]
2. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
3. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783 [TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
5. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma]. Yamane T; Hino M; Ohta K; Koh KR; Nakamae H; Aoyama Y; Ota T; Kishida T; Mugitani A; Sannomiya Y; Kamitani T; Takubo T; Tatsumi N Gan To Kagaku Ryoho; 2000 Sep; 27(10):1547-55. PubMed ID: 11016000 [TBL] [Abstract][Full Text] [Related]
6. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group. Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723 [TBL] [Abstract][Full Text] [Related]
7. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159 [TBL] [Abstract][Full Text] [Related]
8. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study]. Kitajima H; Nasu K; Tsudo M; Fujimoto M; Hayashi K; Ohno H; Konaka Y; Katsurada T; Arima N; Doi S; Moriguchi T; Fukuhara S Rinsho Ketsueki; 2001 Mar; 42(3):191-8. PubMed ID: 11345781 [TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
10. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Jantunen E; Mahlamäki E; Nousiainen T Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654 [TBL] [Abstract][Full Text] [Related]
11. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D; Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400 [TBL] [Abstract][Full Text] [Related]
12. [Trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients]. Motomura S; Hashimoto C; Kodama F; Maruta A; Sakai R; Fujita H; Tomita N; Fujisawa S; Harano H; Koharazawa H; Fujimaki K; Kanamori H; Ishigatsubo Y Rinsho Ketsueki; 2005 May; 46(5):350-7. PubMed ID: 16444968 [TBL] [Abstract][Full Text] [Related]
13. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. van Besien K; Margolin K; Champlin R; Forman S Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395 [TBL] [Abstract][Full Text] [Related]
14. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945 [TBL] [Abstract][Full Text] [Related]
15. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405 [TBL] [Abstract][Full Text] [Related]
17. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome. Martín C; Torres A; León A; Rubio V; Alvarez MA; Herrera C; Jean-Paul E; Correa MA; Rojas R; Campos R; Serrano J; Romero R; Román J; Guzmán JL; Flores R; Falcón M; Martínez F; Gómez P Bone Marrow Transplant; 1998 Feb; 21(4):375-82. PubMed ID: 9509972 [TBL] [Abstract][Full Text] [Related]
18. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Stamatoullas A; Fruchart C; Khalfallah S; Buchonnet G; Contentin N; Bastit D; Tilly H Bone Marrow Transplant; 1997 Jan; 19(1):31-5. PubMed ID: 9012928 [TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973 [TBL] [Abstract][Full Text] [Related]
20. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]